Estrogen receptor

From Proteopedia

spinqualitylabelsall models Human estrogen receptor-ligand binding domain (grey) complex with transcription intermediate factor-2 peptide (pink) and estradiol (PDB code 1gwr) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image Crystal structure of estradiol derived metal chelate and estrogen receptor-ligand binding domain complex 2yat Contents 1 Estrogen receptors 2 Structure of estradiol metal chelate and estrogen receptor complex: The basis for designing a new class of SERMs [1] 3 Estrogen receptor α complexed with raloxifene and a corepressor peptide Estrogen receptors (ER) are activated by the hormone estrogen (EST). The activated ER binds DNA and regulates the activity of many genes. There are 2 forms of ER: α and β and ER dimers can be of αα, ββ and αβ. ER is composed of 5 domains: N terminal A/B domain can transactivate transcription without binding estrogen; C domain (DBD) binds to Estrogen response elements of DNA; D domain is a hinge region; E domain is ligand binding (LBD) as well as binding the coactivator and corepressor proteins and transactivates gene transcription. Structure of estradiol metal chelate and estrogen receptor complex: The basis for designing a new class of SERMs [1] Selective estrogen receptor modulators, such as estradiol 17-derived metal complexes, have been synthesized as targeted probes for the diagnosis and treatment of breast cancer. Here, we report the detailed 3D structure of bound with a novel at 2.6Å resolution (PDB ID 2yat). The residues with EPTA-Eu. The hydrogen bonds are shown as white dashed lines. of this structure with the structure of native ligand 17β-estradiol (E2) in the complex of E2/ERα-LBD complex (1ere) reveals that the . The made by additional estrogen receptor residues (e.g. Glu419 of H7 and Glu339 of H3, this depends on subunit), may work together with the E2 17β hydroxyl-His524 hydrogen bond and tighten the neck of the LBP upon binding of the endogenous ligand E2. 4-Hydroxytamoxifen (OHT) is an other selective estrogen receptor modulator. of EPTA-Eu/ERα-LBD complex on OHT/ERα-LBD complex (3ert) shows that there is similar network of hydrogen bonds in both complexes, except for His524 which does not form hydrogen bond with OHT in the OHT/ERα-LBD complex. E2/ERα-LBD (1ere), OHT/ERα-LBD (3ert) and EPTA-Eu/ERα-LBD shows that they overlap well in the majority portions of the domain, but differ significantly in the region of the 'omega loop'. They display different synergistic reciprocating movements, depending on the specific nature of the ligand bound. The structure of estrogen receptor complexed with EPTA-Eu provides important information pertinent to the design of novel functional ER targeted probes for clinical applications. Estrogen receptor α complexed with raloxifene and a corepressor peptide of estrogen receptor α complexed with raloxifene and a corepressor peptide (morph was taken from Gallery of Morphs of the Yale Morph Server).

For more details see

Ivan Koutsopatriy estrogen receptor
C-di-GMP receptors with PilZ domain
For more details on ERβ see Student Project 10 for UMass Chemistry 423 Spring 2015
For more details on ER-Tamoxifen complex see Tamoxifen.

3D structures of estrogen receptor

Updated on 05-May-2017 {{#tree:id=OrganizedByTopic|openlevels=0|

• Estrogen receptor α ligand binding domain

• • 4n1y - ERα LBD – pacific oyster
    
  • 1a52, 1g50 - hERα LBD - human
    
  • 1ere, 1qku - hERα LBD + EST
    
  • 1qkt - hERα LBD (mutant) + EST
    
  • 1uom, 2ayr, 2q70, 2qe4, 2pog, 2r6w, 2r6y, 2qxs, 5u2b, 5tn9, 5tnb - hERα LBD (mutant) + ligand
    
  • 1err, 3ert, 1sj0, 1yim, 1r5k, 1xp1, 1xp6, 1xp9, 1xpc, 1xqc, 1yin, 2ouz, 2iog, 2iok, 3dt3, 3os8, 3os9, 3osa, 5t92, 5t97 - hERα LBD + ligand
    
  • 2bj4, 2jf9, 2jfa, 1pcg - hERα LBD + peptide antagonist
    
  • 2yja - hERα LBD + stapled peptide
    
  • 5hyr - hERα LBD (mutant) + stapled peptide + estradiol
    
  • 2q6j, 2p15, 3erd, 1l2i - hERα LBD + GRIP peptide
    
  • 5krh - hERα LBD + NCAO2 peptide + benzylidene estrone
    
  • 5kri, 5krj, 5krk, 5krl, 5krm, 5kro - hERα LBD (mutant) + NCAO2 peptide + anti-hormone
    
  • 5kcf, 5kct, 5kcu, [[5kcw, 5kd9, 5kcc, 5kcd - hERα LBD (mutant) + NCAO2 peptide + OBHS derivative
    
  • 5kr9 - hERα LBD (mutant) + NCAO2 peptide + coumestrol
    
  • 5krf - hERα LBD (mutant) + peptide + anti-hormone
    
  • 2yat - hERα LBD (mutant) + EST derivative
    
  • 5fqp, 5fqr, 5fqs, 5fqt, 5fqv - hERα LBD (mutant) + antagonist
    
  • 3uuc - hERα LBD + bisphenol
    
  • 3q97 - hERα LBD + LXXLL motif (mutant) + ethoxy triphenylethylene
    
  • 1gwr - hERα LBD + TIF2 peptide + EST
    
  • 2ocf - hERα LBD (mutant) + fibronectin domain 10 + EST
    

• ERα LBD ternary complex with steroid receptor coactivator 1 peptide

• • 3uu7, 3uua, 3uud - hERα LBD (mutant) + nuclear receptor coactivator 1 peptide
    
  • 4dma - hERα LBD (mutant) + nuclear receptor coactivator 1 peptide + inhibitor
    
  • 4mg5, 4mg6, 4mg7, 4mg8, 4mg9, 4mga, 4mgb, 4mgc, 4mgd - hERα LBD (mutant) + nuclear receptor coactivator 1 peptide + ligand
    
  • 4tuz - hERα LBD (mutant) + steroid receptor coactivator 1 peptide + toxin
    
  • 4tv1 - hERα LBD (mutant) + steroid receptor coactivator 1 peptide + preservative
    

• ERα LBD ternary complex with steroid receptor coactivator 2 peptide

• • 2b23 - hERα LBD (mutant) + nuclear receptor coactivator 2 peptide
    
  • 3q95 - hERα LBD (mutant) + nuclear receptor coactivator 2 peptide + EST
    
  • 4iu7, 4iui, 4iv2, 4iv4, 4ivw, 4ivy, 4iw6, 4iw8, 4iwc, 4iwf, 5u2d, 5tld, 5tlf, 5tlg, 5tll, 5tlm, 5tlo, 5tlp, 5tlt, 5tlu, 5tlv, 5tlx, 5tly, 5tm1, 5tm2, 5tm3, 5tm4, 5tm5, 5tm6, 5tm7, 5tm8, 5tm9, 5tml, 5tmo, 5tmm, 5tmq, 5tmr, 5tms, 5tmt, 5tmu, 5tmv, 5tmw, 5tmz, 5tn1, 5tn3, 5tn4, 5tn5, 5tn6, 5tn7, 5tn8 - hERα LBD (mutant) + nuclear receptor coactivator 2 peptide + inhibitor
    
  • 2g5o - hERα LBD + nuclear receptor coactivator 2 peptide + EST derivative
    
  • 2qgt - hERα LBD (mutant) + nuclear receptor coactivator 2 peptide + EST derivative
    
  • 5kce - hERα LBD (mutant) + nuclear receptor coactivator 2 peptide + OBHS derivative
    
  • 1gwq, 2fai, 2g44, 2qzo - hERα LBD + nuclear receptor coactivator 2 peptide + ligand
    
  • 3l03, 3hm1, 3hlv, 1zky, 2b1v, 2b1z, 2qa6, 2qab, 2qgw, 2qh6, 2qr9, 2qse, 2qxm - hERα LBD (mutant) + nuclear receptor coactivator 2 peptide + ligand
    
  • 2qa8 - hERα LBD (mutant) + steroid receptor coactivator 2 peptide + genistein
    
  • 4pp6, 4ppp, 4pps - hERα LBD (mutant) + steroid receptor coactivator peptide 2 + resveratrol derivative
    

• ERα LBD ternary complex with steroid receptor coactivator 3 peptide

• • 1x7r - hERα LBD + steroid receptor coactivator 3 peptide + genistein
    
  • 1x7e - hERα LBD + nuclear receptor coactivator 3 peptide + ligand
    

• Estrogen receptor β ligand binding domain

• • 1qkm - hERβ LBD + genistein
    
  • 1qkn, 1hj1 - ERβ LBD + ligand – rat
    
  • 1nde, 1u3q, 1u3r, 1u3s, 2giu, 2i0g, 2i0j, 2jj3, 2z4b, 2qtu - hERβ LBD + ligand
    
  • 2yly - hERβ LBD + sulfonamide agonist
    
  • 2fsz - hERβ LBD (mutant) + ligand
    
  • 2yja, 2yjd - hERβ LBD + stapled peptide
    
  • 4j24, 4j26 - hERβ LBD + peptide
    

• ERβ LBD ternary complex with steroid receptor coactivator peptide

• • 1l2j - hERβ LBD + steroid receptor coactivator peptide + nonsteroidal EST
    
  • 2j7x, 3oll, 3ols - hERβ LBD + steroid receptor coactivator peptide + EST
    
  • 1u9e - hERβ LBD + steroid receptor coactivator peptide
    
  • 1x76, 1x78, 1x7b, 1yy4, 1yye, 1zaf, 2j7y, 2nv7, 3omo, 3omp, 3omq - hERβ LBD + steroid receptor coactivator peptide + ligand
    
  • 1x7j - hERβ LBD + steroid receptor coactivator peptide + genistein

• Estrogen receptor α DNA binding domain

• • 1hcp – hERα DBD – NMR
    
  • 1hcq, 4aa6 – hERα DBD + DNA
    

Reference

1. ↑ Li MJ, Greenblatt HM, Dym O, Albeck S, Pais A, Gunanathan C, Milstein D, Degani H, Sussman JL. Structure of estradiol metal chelate and estrogen receptor complex: The basis for designing a new class of selective estrogen receptor modulators. J Med Chem. 2011 Apr 7. PMID:21473635 doi:10.1021/jm200192y